Form D · Biotechnology
Bio Usawa Inc.
San Francisco, CA · CIK 0002095500
Offering snapshot reported Jan 27, 2026 · SEC filing
- Reported sold
- $500K Indefinite offering
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Oct 30, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 27, 2026 | Amendment | $500,000 | No comparison | 7 | SEC filing |
| Dec 17, 2025 | Initial | $403,900 | No comparison | 5 | SEC filing |
| Dec 17, 2025 | Initial | $1,705,000 | No comparison | 25 | SEC filing |
| Dec 17, 2025 | Initial | $450,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-567116
Source: Form D, filed Jan 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vincent Ancinetti | Director |
| Menghis Bairu | Director, Executive |
| Richard Chin | Director |
| John Hautman | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Pine Street Suite 1250
San Francisco, CA, 94111
San Francisco, CA, 94111